Soft Tissue Sarcoma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 470 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Soft Tissue Sarcoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Soft Tissue Sarcoma - Pipeline Review, H2 2015', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Soft Tissue Sarcoma Overview 10
Therapeutics Development 11
Pipeline Products for Soft Tissue Sarcoma - Overview 11
Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12
Soft Tissue Sarcoma - Therapeutics under Development by Companies 13
Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 18
Soft Tissue Sarcoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Soft Tissue Sarcoma - Products under Development by Companies 23
Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 29
Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 30
A. Menarini Industrie Farmaceutiche Riunite Srl 30
Advanced Proteome Therapeutics Corporation 31
Advenchen Laboratories, LLC 32
Altor BioScience Corporation 33
Amgen Inc. 34
Arog Pharmaceuticals, Inc. 35
Bayer AG 36
Bellicum Pharmaceuticals, Inc. 37
Boehringer Ingelheim GmbH 38
CASI Pharmaceuticals Inc. 39
Celgene Corporation 40
Cell Medica Limited 41
Cellceutix Corporation 42
Cellectar Biosciences, Inc. 43
CytRx Corporation 44
Daiichi Sankyo Company, Limited 45
Double Bond Pharmaceutical International AB 46
Eisai Co., Ltd. 47
Eli Lilly and Company 48
EpiZyme, Inc. 49
Exelixis, Inc. 50
F. Hoffmann-La Roche Ltd. 51
Gem Pharmaceuticals, LLC 52
GlaxoSmithKline Plc 53
Immune Design Corp. 54
Karyopharm Therapeutics, Inc. 55
Loxo Oncology, Inc. 56
Lytix Biopharma AS 57
MedImmune, LLC 58
Merck & Co., Inc. 59
Merrimack Pharmaceuticals, Inc. 60
Mirati Therapeutics Inc. 61
MolMed S.p.A. 62
Morphotek, Inc. 63
Northwest Biotherapeutics, Inc. 64
Novartis AG 65
Noxxon Pharma AG 66
OncoTherapy Science, Inc. 67
Onxeo SA 68
Pfizer Inc. 69
Pharma Mar, S.A. 70
Philogen S.p.A. 71
Plexxikon Inc. 72
Polaris Pharmaceuticals, Inc. 73
Recombio S.L 74
Rigontec GmbH 75
Sanofi 76
Shionogi & Co., Ltd. 77
Siena Biotech S.p.A. 78
Sigma-Tau S.p.A. 79
Sumitomo Dainippon Pharma Co., Ltd. 80
Targovax AS 81
Threshold Pharmaceuticals, Inc. 82
TRACON Pharmaceuticals, Inc. 83
Vicore Pharma AB 84
Soft Tissue Sarcoma - Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Combination Products 86
Assessment by Target 87
Assessment by Mechanism of Action 94
Assessment by Route of Administration 99
Assessment by Molecule Type 101
Drug Profiles 103
afatinib dimaleate - Drug Profile 103
AL-3818 - Drug Profile 108
aldoxorubicin hydrochloride - Drug Profile 110
ALT-836 - Drug Profile 113
APC-103 - Drug Profile 115
belinostat - Drug Profile 116
BI-853520 - Drug Profile 119
C-21 - Drug Profile 120
cabazitaxel - Drug Profile 122
cabozantinib s-malate - Drug Profile 124
cancer vaccine - Drug Profile 128
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 129
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 130
celyvir - Drug Profile 132
CMD-003 - Drug Profile 134
crenolanib besylate - Drug Profile 136
DCVax-Direct - Drug Profile 138
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 140
DSR-6434 - Drug Profile 141
durvalumab + tremelimumab - Drug Profile 142
efatutazone - Drug Profile 144
emactuzumab - Drug Profile 146
ENMD-2076 - Drug Profile 147
eribulin mesylate - Drug Profile 149
everolimus - Drug Profile 155
evofosfamide - Drug Profile 161
Fibromun - Drug Profile 169
G-100 - Drug Profile 171
GPX-150 - Drug Profile 173
GSK-3174998 - Drug Profile 176
HDM-201 - Drug Profile 177
I131-CLR1404 - Drug Profile 178
ID-LV305 + ID-G305 - Drug Profile 180
ImOl-100 - Drug Profile 182
irinotecan hydrochloride - Drug Profile 183
KM-3174 - Drug Profile 186
KRA-0008 - Drug Profile 190
LK-3 - Drug Profile 191
LOXO-101 - Drug Profile 192
LTX-315 - Drug Profile 194
LV-305 - Drug Profile 196
MAT-303 - Drug Profile 197
mocetinostat - Drug Profile 198
MVXONCO-1 - Drug Profile 201
NGR-hTNF - Drug Profile 202
NOV-110501 - Drug Profile 206
NOXS-93 - Drug Profile 207
olaratumab - Drug Profile 208
ONCOS-102 - Drug Profile 211
ontuxizumab - Drug Profile 213
OTSA-101 - Drug Profile 215
paclitaxel albumin bound - Drug Profile 216
palbociclib - Drug Profile 220
panobinostat - Drug Profile 224
pazopanib hydrochloride - Drug Profile 230
pembrolizumab - Drug Profile 236
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 245
PF-03084014 - Drug Profile 247
PLX-7486 - Drug Profile 249
regorafenib - Drug Profile 250
ribociclib - Drug Profile 254
roneparstat - Drug Profile 257
S-588410 - Drug Profile 258
SA-083 - Drug Profile 259
sabarubicin - Drug Profile 260
selinexor - Drug Profile 262
SEN-461 - Drug Profile 268
talimogene laherparepvec - Drug Profile 269
tazemetostat - Drug Profile 272
TNF-PEG 20 - Drug Profile 274
trabectedin - Drug Profile 275
TRC-105 - Drug Profile 280
Vaccine for Soft Tissue Sarcoma - Drug Profile 283
vorinostat - Drug Profile 284
Soft Tissue Sarcoma - Recent Pipeline Updates 288
Soft Tissue Sarcoma - Dormant Projects 449
Soft Tissue Sarcoma - Discontinued Products 453
Soft Tissue Sarcoma - Product Development Milestones 454
Featured News & Press Releases 454
Appendix 463
Methodology 463
Coverage 463
Secondary Research 463
Primary Research 463
Expert Panel Validation 463
Contact Us 463
Disclaimer 464

List of Tables

Number of Products under Development for Soft Tissue Sarcoma, H2 2015 17
Number of Products under Development for Soft Tissue Sarcoma - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Development by Companies, H2 2015 (Contd..1) 21
Number of Products under Development by Companies, H2 2015 (Contd..2) 22
Number of Products under Development by Companies, H2 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2015 24
Comparative Analysis by Late Stage Development, H2 2015 25
Comparative Analysis by Clinical Stage Development, H2 2015 26
Comparative Analysis by Early Stage Development, H2 2015 27
Comparative Analysis by Unknown Stage Development, H2 2015 28
Products under Development by Companies, H2 2015 29
Products under Development by Companies, H2 2015 (Contd..1) 30
Products under Development by Companies, H2 2015 (Contd..2) 31
Products under Development by Companies, H2 2015 (Contd..3) 32
Products under Development by Companies, H2 2015 (Contd..4) 33
Products under Development by Companies, H2 2015 (Contd..5) 34
Products under Investigation by Universities/Institutes, H2 2015 35
Soft Tissue Sarcoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 36
Soft Tissue Sarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015 37
Soft Tissue Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2015 38
Soft Tissue Sarcoma - Pipeline by Altor BioScience Corporation, H2 2015 39
Soft Tissue Sarcoma - Pipeline by Amgen Inc., H2 2015 40
Soft Tissue Sarcoma - Pipeline by Arog Pharmaceuticals, Inc., H2 2015 41
Soft Tissue Sarcoma - Pipeline by Bayer AG, H2 2015 42
Soft Tissue Sarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 43
Soft Tissue Sarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 44
Soft Tissue Sarcoma - Pipeline by CASI Pharmaceuticals Inc., H2 2015 45
Soft Tissue Sarcoma - Pipeline by Celgene Corporation, H2 2015 46
Soft Tissue Sarcoma - Pipeline by Cell Medica Limited, H2 2015 47
Soft Tissue Sarcoma - Pipeline by Cellceutix Corporation, H2 2015 48
Soft Tissue Sarcoma - Pipeline by Cellectar Biosciences, Inc., H2 2015 49
Soft Tissue Sarcoma - Pipeline by CytRx Corporation, H2 2015 50
Soft Tissue Sarcoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 51
Soft Tissue Sarcoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2015 52
Soft Tissue Sarcoma - Pipeline by Eisai Co., Ltd., H2 2015 53
Soft Tissue Sarcoma - Pipeline by Eli Lilly and Company, H2 2015 54
Soft Tissue Sarcoma - Pipeline by EpiZyme, Inc., H2 2015 55
Soft Tissue Sarcoma - Pipeline by Exelixis, Inc., H2 2015 56
Soft Tissue Sarcoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 57
Soft Tissue Sarcoma - Pipeline by Gem Pharmaceuticals, LLC, H2 2015 58
Soft Tissue Sarcoma - Pipeline by GlaxoSmithKline Plc, H2 2015 59
Soft Tissue Sarcoma - Pipeline by Immune Design Corp., H2 2015 60
Soft Tissue Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 61
Soft Tissue Sarcoma - Pipeline by Loxo Oncology, Inc., H2 2015 62
Soft Tissue Sarcoma - Pipeline by Lytix Biopharma AS, H2 2015 63
Soft Tissue Sarcoma - Pipeline by MedImmune, LLC, H2 2015 64
Soft Tissue Sarcoma - Pipeline by Merck & Co., Inc., H2 2015 65
Soft Tissue Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 66
Soft Tissue Sarcoma - Pipeline by Mirati Therapeutics Inc., H2 2015 67
Soft Tissue Sarcoma - Pipeline by MolMed S.p.A., H2 2015 68
Soft Tissue Sarcoma - Pipeline by Morphotek, Inc., H2 2015 69
Soft Tissue Sarcoma - Pipeline by Northwest Biotherapeutics, Inc., H2 2015 70
Soft Tissue Sarcoma - Pipeline by Novartis AG, H2 2015 71
Soft Tissue Sarcoma - Pipeline by Noxxon Pharma AG, H2 2015 72
Soft Tissue Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2015 73
Soft Tissue Sarcoma - Pipeline by Onxeo SA, H2 2015 74
Soft Tissue Sarcoma - Pipeline by Pfizer Inc., H2 2015 75
Soft Tissue Sarcoma - Pipeline by Pharma Mar, S.A., H2 2015 76
Soft Tissue Sarcoma - Pipeline by Philogen S.p.A., H2 2015 77
Soft Tissue Sarcoma - Pipeline by Plexxikon Inc., H2 2015 78
Soft Tissue Sarcoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 79
Soft Tissue Sarcoma - Pipeline by Recombio S.L, H2 2015 80
Soft Tissue Sarcoma - Pipeline by Rigontec GmbH, H2 2015 81
Soft Tissue Sarcoma - Pipeline by Sanofi, H2 2015 82
Soft Tissue Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015 83
Soft Tissue Sarcoma - Pipeline by Siena Biotech S.p.A., H2 2015 84
Soft Tissue Sarcoma - Pipeline by Sigma-Tau S.p.A., H2 2015 85
Soft Tissue Sarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 86
Soft Tissue Sarcoma - Pipeline by Targovax AS, H2 2015 87
Soft Tissue Sarcoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 88
Soft Tissue Sarcoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 89
Soft Tissue Sarcoma - Pipeline by Vicore Pharma AB, H2 2015 90
Assessment by Monotherapy Products, H2 2015 91
Assessment by Combination Products, H2 2015 92
Number of Products by Stage and Target, H2 2015 94
Number of Products by Stage and Mechanism of Action, H2 2015 101
Number of Products by Stage and Route of Administration, H2 2015 106
Number of Products by Stage and Molecule Type, H2 2015 108
Soft Tissue Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015 294
Soft Tissue Sarcoma - Dormant Projects, H2 2015 455
Soft Tissue Sarcoma - Dormant Projects (Contd..1), H2 2015 456
Soft Tissue Sarcoma - Dormant Projects (Contd..2), H2 2015 457
Soft Tissue Sarcoma - Dormant Projects (Contd..3), H2 2015 458
Soft Tissue Sarcoma - Discontinued Products, H2 2015 459